Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications by Nick Boyne, Alison Duke, Jack Rea, Adam Khan, Alec Young, Jared Van Vleet, Matt Vassar

“…However, adverse event (AE) reporting for these therapies often lacks transparency, raising concerns about the accuracy of safety data. …”
Get full text

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial by Graham McIlroy, Charlotte Gaskell, Aimee Jackson, Emily Yafai, Rachel Tasker, Catherine Thomas, Sonia Fox, Rebecca Boucher, Fitsum Ghebretinsea, Claire Harrison, Adam J. Mead, Mary Frances McMullin

“…It has shown activity in MF and is well-tolerated, but combination with other therapies is likely needed to achieve clonal remission. …”
Get full text

A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease by Fernando Sierra-Arango, D. M. Castaño, Jennifer D. Forero, Erika D. Pérez-Riveros, Gerardo Ardila Duarte, Maria L. Botero, Andres Cárdenas, Jose De la Hoz-Valle

“…N-of-1 trials in chronic pathologies including GERD are recommended due to their potential value as systematic methods that evaluate therapies without strong scientific evidence.…”
Get full text

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib by Jing Zhang, Zequn Wang, Xihua Wei, Mengyuan Han, Ribai Yan, Lijie Ma, Yan Pan

“…Despite significant advancements in therapeutic strategies and a deeper understanding of targeted therapies in recent years, tumor resistance remains an inevitable challenge, leading to poor prognostic outcomes. …”
Get full text

Evaluation of Inflammatory Markers and Clinical Outcomes in COVID-19 Patients with Concurrent <i>Clostridioides difficile</i> Infection: A Comparative Cohort Analysis by Flavia Ignuta, Adrian Vlad, Teodor Cerbulescu, Stana Loredana, Felix Bratosin, Ovidiu Rosca, Lavinia Stelea, Daciana Nistor

“…Timely recognition of <i>C. difficile</i> co-infection and use of targeted anti-inflammatory and supportive therapies may improve patient management. Future studies should expand on these findings to optimize care and guide therapeutic strategies.…”
Get full text

Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway by Adrish Sen, Salmaan Khan, Stefano Rossetti, Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz, Lance Laing

“…Gedatolisib, as a single agent and in combination with other therapies, reported promising preliminary efficacy and safety in various solid tumor types. …”
Get full text

A comprehensive analysis of molecular characteristics of hot and cold tumor of gastric cancer by Chenxi Lv, Tianwei Chen, Jiangtao Li, Yuqiang Shan, Hong Zhou

“…However, a detailed molecular characterization of the tumor immune microenvironment in GC is essential to further optimize these therapies and enhance their efficacy. Methods Consensus clustering was utilized to classify GC patients into distinct immune states, followed by an in-depth analysis of differences in mutation profiles, copy number variations, and DNA methylation patterns. …”
Get full text

Comparative analysis of dominant gut microbiota in Inflammatory Bowel Disease patients and healthy individuals: A case-control study by Alireza Ahmadi, Ebrahim Kouhsari, Shabnam Razavi, Nima Mohamadzadeh, Sima Besharat, Mohammad Ali Vakili, Taghi Amiriani

“…The identification of specific bacterial imbalances provides a foundation for developing microbiota-based therapies, such as probiotics, prebiotics, and fecal microbiota transplantation, as potential interventions for restoring microbial balance and mitigating disease progression. …”
Get full text

Adenoid cystic carcinoma of the breast, from diagnosis to management: a case report by Mendoza-Urbano Diana Marcela, Cañon Diana, Palazuelos Gloria Ines, Torres Fabio, Wills Beatriz, Rodriguez-Urrego Paula Andrea

“…Multidisciplinary management remains crucial as the cornerstone of care, especially for offering therapies tailored to each patient’s specific needs.…”
Get full text

SUMO modified ETV1 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by facilitating CCL2 transcription in esophageal squamous cell carcinoma ce... by Tianci Han, Xiaoqi Guo, Junwei Xie, Wei Tong, Liang Zhang

“…Conclusions Our data deciphered the mechanism of ETV1-mediated M2 macrophage infiltration in the TME of ESCC, which has important implications for the development of novel prognostic and therapeutic targets to optimize current therapies against ESCC.…”
Get full text

Integrating single-cell RNA-seq and bulk RNA-seq to explore prognostic value and immune landscapes of methionine metabolism-related signature in breast cancer by Yanxian Gao, Ziyu Feng, Hailong Zhao, Xinghai Liu, Muyu Zhu, Xiafei Yu, Xiaoan Liu, Xian Wu, Jing Tao

“…BackgroundNeoadjuvant, endocrine, and targeted therapies have significantly improved the prognosis of breast cancer (BC). …”
Get full text

Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn [ver... by ShamaPrasada K, Reshma Kumarchandra, Vasavi Kumblekar, K Sreedhara Ranganath Pai, Suman Manandhar, Sharada Rai, Rajeshwari Shastry

“…This increased burden demands new targeted therapies with novel compounds either synthetically produced or derived from indigenous plants, which could be a promising approach for the development of drugs. …”
Get full text

Genetic Diversity, Repeat Motifs, and Natural Selection at the C-Terminal Knob-Associated Histidine Rich Protein (KAHRP) of Plasmodium falciparum Clinical Samples from Saudi Arabia by Saad M. Bin Dajem, Md Atique Ahmed, Marie Fe F Bohol, Syeda Wasfeea Wazid, Mohammed I. Shafeai, Fuad H. Rudiny, Ali M. Motaen, Kareem Morsy, Hani Alothaid, Ahmed A. Al-Qahtani

“…Since this is the first study to report on genetic diversity of C-terminal PfKAHRP interaction domain and the repeat motifs from clinical samples in Saudi Arabia, it will contribute towards the rational design of antiadhesion drug therapies for P. falciparum malaria.…”
Get full text

Oral medications for the treatment of postural orthostatic tachycardia syndrome; a systematic review of studies before and during the COVID-19 pandemic by Benjamin C. Pierson, Kyle Apilado, Kyle Apilado, M. Alaric Franzos, M. Alaric Franzos, Rhonda Allard, James D. Mancuso, David Tribble, David Tribble, David Saunders, Tracey Perez Koehlmoos, Tracey Perez Koehlmoos

“…Particular areas of inquiry include differential efficacy of recommended therapies based on POTS subtypes, and a need for treatments directly targeting the underlying autonomic nervous system dysfunction.Systematic review registrationPROSPERO, identifier CRD42024505967, https://www.crd.york.ac.uk/prospero/display_record.php?…”
Get full text

Computational network analysis of two popular skin cancers provides insights into the molecular mechanisms and reveals common therapeutic targets by Md Sujan Mahmud, Bikash Kumar Paul, Md. Rakibul Hasan, K.M. Tanjida Islam, Imran Mahmud, Shahin Mahmud

“…Therefore, these findings may guide future research in understanding and developing targeted therapies for both conditions.…”
Get full text

Comparative evaluation of BacT/ALERT VIRTUO and BACTEC FX400 blood culture systems for the detection of bloodstream infections by Yurong Qin, Yiwen Liao, Jingfang Zhou, Weijiang Liu, Huimin Chen, Xiaoli Chen, Weisha Wang, Ni Zhang, Yunhu Zhao, Liang Wang, Bing Gu, Suling Liu

“…These findings emphasize VIRTUO’s effectiveness in enhancing diagnostic accuracy, achieving faster time to detection, and expanding the spectrum of detected organisms, thereby facilitating the quicker initiation of appropriate therapies, supporting precise clinical decision-making, and ultimately improving patient outcomes.IMPORTANCEOur study conducted a critical evaluation of advanced blood culture technologies for managing bloodstream infections (BSI). …”
Get full text

Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trialResearch... by Katrine Lundby Høyer, Simon Mark Dahl Baunwall, Ditte Smed Kornum, Mette Winther Klinge, Asbjørn Mohr Drewes, Knud Bonnet Yderstræde, Louise Bruun Thingholm, Martin Steen Mortensen, Susan Mikkelsen, Christian Erikstrup, Christian Lodberg Hvas, Klaus Krogh

“…Summary: Background: Diabetic gastroenteropathy is associated with nausea, vomiting, bloating, pain, constipation, and diarrhoea. Current therapies are scarce. We tested faecal microbiota transplantation (FMT) for patients with type 1 diabetes and gastroenteropathy. …”
Get full text

Identification of determinants that allow maintenance of high-level fluoroquinolone resistance in Acinetobacter baumannii by Efrat Hamami, Wenwen Huo, Juan Hernandez-Bird, Arnold Castaneda, Jinna Bai, Sapna Syal, Juan C. Ortiz-Marquez, Tim van Opijnen, Edward Geisinger, Ralph R. Isberg

“…These results point to strategies for developing therapies that combine known antibiotics with drugs that target proteins important for survival of strains hyper-expressing efflux pumps.…”
Get full text

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes by Jennifer Cattaneo, Paolo Forte, Giovanni Forte, Chiara M. Eandi

“…Abstract Background This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month. …”
Get full text

Treatment patterns for chronic obstructive pulmonary disease under the tiered medical system by Xiaoli Wang, Xingru Zhao, Tianqi Cen, Yi Yu, Zhiwei Xu, Lijun Shen, Ziqi Wang, Paul Jones, Quncheng Zhang, Yunxia An, Xiaoju Zhang

“…In addition, the use of inhalation therapies containing inhaled corticosteroids (ICS) in China’s primary care is notably lower (16.9%) than the United States, the United Kingdom, and other middle-to-high-income countries (29.5-57.0%). …”
Get full text